The trade war between the United States and China has lasted for more than one year — and a resolution is nowhere in sight.World Economyread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Investors await the Fed's latest decision on monetary policy, set to be released on Wednesday stateside. The U.S. central bank is widely expected to cut rates by 25 basis...Asia Marketsread more
TransferWise posted an annual net profit of £10.3 million on revenues of £179 million.Technologyread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Ligand gets royalties on sales of Amgen's Kyprolis drug, which treats a form of incurable blood cancer. The drug generated $172 million in revenue in the second quarter, according to Reuters, and was expected to generate peak annual sales of about $2.3 billion.
Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression-free survival versus Velcade in patients who had not yet been treated for the disease.
"We remain committed to exploring Kyprolis in combination with other agents to advance the treatment of multiple myeloma," Harper said.
Kyprolis has already been approved by the U.S. Food and Drug Administration for patients with relapsed or refractory multiple myeloma, who have previously been treated.
Dr. Andrzej Jakubowiak from the University of Chicago Medical Center said during a conference call that although the results were disappointing, they were predictable to some extent.
"This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially important," he said.
Kyprolis is also being tested in a separate late-stage trial in combination with Celgene's Revlimid and the steroid dexamethasone, or KRd.
Shares of Ligand have fallen 8 percent for the year, closing at $99.64 a share. Amgen was down about 1 percent for the day, but up more than 5 percent for the year, closing at $171.63 a share.
--Reuters contributed to this report.